Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nomination to Nokian Tyres' management team

Nokian Tyres plc Stock Exchange Release 18 May, 2016 09.30 a.m. Timo Tervolin has been appointed as Vice President, Strategy and Corporate Development and a member of Nokian Tyres' management team. His responsibilities will include leading the company's strategy process and strategic programs, mergers and acquisitions, and monitoring markets and competition. Tervolin is currently working for Ingram Micro, the leading global technology distributor based in Irvine, California, leading Ingram Micro’s mergers and acquisitions team. He has substantial international experience in strategy

INVISIO receives SEK 9 million order from existing customer within NATO

Stockholm, May 18, 2016  INVISIO (IVSO) has received a new order for communications systems and accessories from an existing customer within NATO. The order value amounts to approximately SEK 9 million and delivery is scheduled for the second half of 2016."The new order from the customer is a clear indicator of confidence in INVISIO's solutions and expertise to protect the wearer's hearing and secure means of communication in extreme Environments", says Lars Højgård Hansen, CEO of INVISIO.The order includes communications system with headsets for use with a radio. The system

Pooyandegan Pezeshki Pardis to distribute Biohit GastroPanel®-test in Iran

Biohit Oyj Press Release May 18, 2016 at 9:30 am local time (EEST)  Biohit Oyj and Pooyandegan Pezeshki Pardis (3P) have signed an agreement for the distribution of the Biohit Unified GastroPanel[®] test in Iran. GastroPanel[®] innovation is a stomach health test. The test is performed from a blood sample and designed for diagnosis of Helicobacter pylori infection and atrophic gastritis, irrespective whether caused by H. pylori infection or autoimmune disease. The test also enables to assess whether the patient is at risk for gastric or esophageal cancer, peptic ulcer disease or

Change to SimCorp’s Board of Directors

SimCorp announces that Frank Cohen, President EMEA at SAP AG, has decided to resign from SimCorp’s Board of Directors with immediate effect. The reason for the resignation is a conflict of interest pertaining to a European Asset Manager. Franck Cohen was elected as a new member of the Board of Directors at the annual general meeting on April 1, 2016.  Enquiries regarding this announcement should be addressed to:Jesper Brandgaard, Chairman of the Board of Directors, SimCorp A/S (+45 4442 3295)           Klaus Holse, Chief Executive Officer, SimCorp A/S (+45 3544 8802, +45 2326

Company Announcement no. 47, 2016 – Investor Presentation, Q1 2016

Nordea Kredit hereby publishes the Investor Presentation for Q1 2016. Publication of the LTV report ceased by the end of 2014. For information on LTV please refer to Nordea Kredit’s ECBC National Transparency Templates, these Templates can be accessed at Nordea Kredit webpage under Investor Information. For further information please contact Finn Nicolaisen, phone +45 3333 1625 or Juho-Pekka Jääskeläinen, phone +45 3333 1626. Yours faithfully Nordea Kredit Realkreditaktieselskab

Sale of shares in Bravida Holding AB (publ)

Press release, Stockholm, 18 May 2016 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER OF SECURITIES IN THE UNITED STATES OR ANY OTHER JURISDICTION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Bravissima Holding AB (the “Seller”) has sold in total 22,000,000 ordinary shares in Bravida Holding AB (publ), a company listed

Tieto expands its Security Services ecosystem – enables customers to tap into more than 63 million sensors monitoring worldwide attack activity

Tieto grows its ecosystem within Security Services. By using Symantec services in its offerings Tieto’s gives its customers’ an access to an industry leading threat intelligence network and over 1 000 security professionals that detect and predict global cyber-attacks 24/7.Cyber attacks are becoming more frequent and sophisticated – and they know no borders. Typically companies experience 2 - 4 targeted attacks per year* and increasingly need to be more prepared and agile. To detect incidents and take appropriate action fast, Tieto expands its Security Operations Centre, an end-to-end

INTERIM REPORT JANUARY - MARCH 2016

JANUARY – MARCH 2016 - Net sales amounted to SEK 79.3 (70.8) million- EBITDA was SEK 5.2 (3.7) million- Basic earnings per share were SEK -0.02 (-0.06) SIGNIFICANT EVENTS Increase in net sales and gross profit- Net sales increased by 12% to SEK 79.3 million- Gross profit increased by 17% to SEK 38.4 million Positive EBITDA of SEK 5.2 million for the period- Continued sales growth with a healthy gross margin- Higher volumes provide economies of scale Future outlook 2016- Maintained net sales- Positive EBITDAOPERATIONS Sales and profitability continued to

TOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL

ASTRAZENECA PROVIDES TOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL IN ADVANCED GASTRIC CANCER 18 May 2016 AstraZeneca today announced that Lynparza (olaparib) in combination with paclitaxel chemotherapy, compared with paclitaxel chemotherapy alone, did not meet the primary endpoint of overall survival (OS) in the Phase III GOLD trial in advanced gastric cancer patients, in either the overall population or patients whose tumour tested negative for Ataxia-Telangectasia Mutated (ATM) protein. Whilst there was a numerical survival trend in the Lynparza plus paclitaxel arm, it did not meet

Wilson Therapeutics announces that the ongoing Phase II study has been fully enrolled

Wilson Therapeutics AB (publ), announces that the company’s ongoing Phase II clinical trial evaluating the safety and efficacy of Decuprate® (bis-choline tetrathiomolybdate; WTX101) in Wilson Disease patients has been fully enrolled.WTX101-201 is a Phase II clinical trial evaluating the efficacy and safety of Decuprate® monotherapy dosed once daily in newly-diagnosed patients with Wilson Disease, aged 18 years and older, who previously have been treated with a standard of care agent for up to two years,. The study is being conducted at 11 sites in the U.S. and Europe, and will follow

Castellum announces terms for rights issue

This press release may not be announced, published or distributed, in whole or in part, directly or indirectly, in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Singapore, South Africa or any other country where such publication or distribution would violate applicable laws or rules or would require additional documents to be prepared or registered or require any other actions to be taken, in addition to the requirements under Swedish law. This press release is not a prospectus but an announcement of the board of directors’ of Castellum conditional resolution to carry

Stora Enso invests for strategic growth in consumer packaging boards

Stora Enso is investing EUR 70 million in Imatra Mills, Finland to increase capacity for producing extrusion coated products, and further enhance its position as a leading global supplier of premium paperboards to its customers.STORA ENSO OYJ STOCK EXCHANGE RELEASE 18 May 2016 at 9.00 EET Stora Enso will invest a total of approximately EUR 70 million in a new polyethylene (PE) extrusion coating plant and an automated roll warehouse (ARW) at Imatra mills in Finland. Extrusion coating is a process used to enhance the functionality of paperboard packaging by creating barrier properties for

Ericsson's nomination committee appointed

Ericsson's (NASDAQ:ERIC) Nomination Committee for the Annual General Meeting 2017 has been appointed in accordance with the Instruction for the Nomination Committee resolved by the Annual General Meeting 2012. The Nomination Committee consists of: · Petra Hedengran, Investor AB; · Johan Held, Afa Försäkring; · Leif Johansson, the Chairman of the Board of Directors; · Bengt Kjell, AB Industrivärden and Handelsbankens Pensionsstiftelse; and · Anders Oscarsson, AMF - Försäkring och Fonder. Petra Hedengran is the Chairman of the Nomination Committee. Shareholders who

Stillfront Group AB: Stillfront's Coldwood develops sequel to Unravel

PRESS RELEASEMAY 18, 2016 New adventures for Unravel's Yarny from Coldwood and EA Electronic Arts Inc (NASDAQ:EA) and Coldwood Interactive today announce the development of a sequel to Unravel to be developed by Coldwood Interactive for Electronic Arts. Coldwood Interactive is the studio behind Unravel - the highly acclaimed puzzle platformer game developed for EA, that was launched February 9, 2016. Unravel has received much praise and is particularly recognized for the beautiful graphics with stunning environments inspired by the nature of northern Sweden, its folk music inspired

Herantis Pharma initiates patient recruitment for clinical study with Lymfactin® in breast cancer associated lymphedema

Herantis Pharma initiates patient recruitment for clinical study with Lymfactin® in breast cancer associated lymphedema Herantis Pharma PlcCompany release 18 May 2016 at 9:00 am Herantis Pharma Plc ("Herantis") has started patient recruitment for its clinical study with Lymfactin® for the treatment of breast cancer associated secondary lymphedema. While the primary endpoint of the study is to assess the safety and tolerability of Lymfactin® the study will also assess the preliminary efficacy of the treatment. "Lymfactin® is a prime example of regenerative medicine", explains

Viking Line's Interim Report for the period January - March 2016.

Viking Line Abp              INTERIM REPORT          18.5.2016, 9.00 AM VIKING LINE'S INTERIM REPORT FOR THE PERIOD JANUARY - MARCH 2016.Consolidated sales of the Viking Line Group during the first quarter, January 1 – March 31, 2016, increased by 1.8 per cent to 106.9 million euros compared to the same quarter of 2015 (EUR 105.0 M). Other operating revenue amounted to EUR 1.5 M (0.1). Operating income amounted to EUR -11.6 M (-9.8). Net financial items totalled EUR -1.5 M (-0.5). Consolidated income before taxes amounted to EUR -13.1 M (-10.4). Income after taxes totalled EUR -10.5 M (

Orkla ASA: Mandatory notification of trade - options

On 13 May, in connection with Orkla's former management option programme, 30,000 options in Orkla-shares were exercised at a strike price of NOK 40.03 per share.After this transaction, the total number of options issued in Orkla shares under the management option programme is 1,400,000. Orkla owns 1,618,135 treasury shares. Orkla ASAOslo, 18 May 2016Ref.:Investor RelationsElise HeidenreichTel.: +47 951 41 147 This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Kværner ASA: Acquisition of own shares

18 May 2016 - Kværner ASA has on Friday 13 May in connection with the company's incentive programme for employees purchased 185 000 own shares in the open market at an average price of NOK 7.51 per share. Following the transaction, Kværner ASA holds a total of 2 455 341 own shares. ENDS For further information, please contact: Investor Relations:Ingrid Aarsnes, VP Investor Relations & Communications, Kvaerner, Tel: +47 67 59 50 46,Mob: +47 950 38 364, email: ir@kvaerner.com Media:Torbjørn Andersen, Head of Communications, Kvaerner, Mob: +47 928 85 542,email: torbjorn.

Interim Report 1 January – 31 March 2016

3 months ended 31 March 2016 · Local currency sales increased by 10% and Euro sales decreased by 1% to €305.8m (€307.8m). · Number of active consultants decreased by 9% to 3.1m. · EBITDA amounted to €27.7m (€23.0m). · Operating margin was 6.9% (5.6%), impacted by -370 bps from currencies, and operating profit €21.1m (€17.2m). · Net profit was €10.7m (€11.2m) and EPS €0.19 (€0.20). · Cash flow from operating activities was €21.5m (€24.1m). · During the quarter $80.0m of the long-term debt was prepaid, corresponding to a cash outflow of €56.0m. · The year to date

SDRL - Seadrill Agrees to Debt-for-Equity Exchange

Hamilton, Bermuda, May 18, 2016 - Seadrill Limited ("Seadrill" or the "Company") announces today that it has entered into a privately negotiated exchange agreement with certain holders of its outstanding 5-5/8% Senior Notes due 2017 (the "2017 Notes"), pursuant to which the Company has agreed to issue a total of 8,184,340 new shares of its common stock, par value $2.00 per share, in exchange for $55.0 million principal amount of the 2017 Notes in accordance with Section 3(a)(9) of the U.S. Securities Act of 1933, as amended (the "Exchange"). Settlement is expected to occur on May 20,

RepRisk releases Special Report on Malaysia

Report analyzes the environmental, social, and governance (ESG) risks in Malaysia’s three key sectorsZurich, Switzerland – May 18, 2016 – RepRisk, the leading provider of dynamic business intelligence on ESG risks, has released its Special Report on Malaysia, the third in a series of reports on the Association of Southeast Asian Nations (ASEAN), an economic and political organization of ten countries. The report highlights the ESG challenges facing Malaysia and its three most exposed sectors – Food and Beverage, Forestry, and Utilities. These sectors all play a crucial role in the

Nordic Nanovector announces first patient enrolled in the last cohort (Arm 4) of expanded Phase 1/2 study of Betalutin® in NHL patients

Oslo, Norway, 18 May 2016 Nordic Nanovector ASA (OSE: NANO), a biotechnology company focusing on the development of novel targeted therapeutics in haematology and oncology, announces that the first patient has been enrolled into the second of the two new arms, and the last cohort, of its expanded Lymrit 37-01 clinical study with Betalutin®. Betalutin® is a novel anti-CD37 targeting Antibody Radionuclide Conjugate in development for the treatment of major types of non-Hodgkin’s lymphoma (NHL), including Follicular Lymphoma (FL). The final cohort (Arm 4) is designed to investigate

Starbreeze AB (publ) Q1 report January 1 - March 31 2016

The full Q1 report is available at www.starbreeze.com/investor-relations/ . Financial statements in English are available at the end of this document.  CHANGED FISCAL YEARNote that in accordance with the decision taken on the Annual General Meeting in November 2015, this is the first quarterly report after changing the company’s fiscal year to calendar year. The comparative period Q1 2015 corresponds to January-March 2015, previously named Q3 2014/2015.The next report to be issued will thus be Q2 2016 and will be released on August 25 2016. · Pressrelease for download:  2016-05-

Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities

Valby, Denmark, 17 May 2016 - H. Lundbeck A/S (Lundbeck) hereby reports transactions made by executives and persons and legal entities closely associated to them with shares and linked securities in Lundbeck, cf. Section 28a of the Danish Securities Trading Act.Name:                                                                                    Anders Gersel Pedersen Job position:                                                                         Executive Vice President, member of the Executive

There are no items matching the current filter
There are no more items matching the current filter
Back to top